RxDoctor Payments DataLook up a doctor →

David Waterhouse, MD

Hematology & Oncology · Cincinnati, OHNPI 1578557864

Payments from drug & device makers

$5,734,264in general payments, 2019–2025

Across 3,326 payments — averaging $1724.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1.7M
  • Merck$1.1M
  • E.r. Squibb & Sons, L.L.C.$584K
  • Eisai Inc.$489K
  • Johnson & Johnson$432K
  • Pfizer$254K
  • plus $1.2M from 51 others
$168,823in research payments, 2019–2025

Across 25 payments — averaging $6752.94 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$149K
  • Bristol Myers Squibb$13K
  • Amgen$7K
  • Eli Lilly$73

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen209$1,702,954
Merck649$1,082,470
E.r. Squibb & Sons, L.L.C.193$584,002
Eisai Inc.751$488,577
Johnson & Johnson(2 entities)407$431,809
Pfizer250$254,123
Takeda Pharmaceuticals U.S.A., Inc.70$232,802
Janssen Research & Development, LLC239$228,895
AstraZeneca94$162,454
EMD Serono, Inc.101$147,732
Seagen Inc.53$72,060
Genentech, Inc.7$51,297
Puma Biotechnology, Inc.20$46,421
Janssen Scientific Affairs, LLC50$46,059
Regeneron12$41,900
Sanofi23$26,098
GSK7$17,680
Fresenius Kabi USA, LLC22$17,221
Lilly USA, LLC8$16,546
Mirati Therapeutics, Inc.20$16,141
Jazz Pharmaceuticals Inc.7$12,813
Bristol Myers Squibb10$10,821
Viiv Healthcare Company1$9,500
Eli Lilly3$5,123
Novartis20$4,856
Gilead(2 entities)10$3,849
Astrazeneca UK Limited5$2,890
Taiho Oncology, Inc.3$2,854
AbbVie13$2,641
Exelixis Inc.2$2,450
Regeneron Healthcare Solutions, Inc.2$2,306
Bayer5$1,627
AVEO Pharmaceuticals, Inc.6$1,606
Daiichi Sankyo Inc.5$1,373
Avyxa Pharma, LLC1$1,000
Genentech USA, Inc.6$238
Astellas Pharma US Inc8$219
Bioprotect Medical, Inc.1$117
Myovant Sciences Inc.1$95
Incyte Corporation4$70
Cumberland Pharmaceuticals, Inc.2$64
Tempus AI, Inc3$64
Progenics Pharmaceuticals, Inc.3$63
Sumitomo Pharma America, Inc.3$51
Adaptive Biotechnologies Corporation2$50
Array Biopharma Inc3$48
Stemline Therapeutics Inc.2$37
Pharmacosmos Therapeutics Inc.1$35
G1 Therapeutics, Inc.1$29
Dendreon Pharmaceuticals LLC1$29
Sun Pharmaceutical Industries Inc.1$20
Ipsen Biopharmaceuticals, Inc1$16
Deciphera Pharmaceuticals Inc.1$16
Azurity Pharmaceuticals, Inc.1$15
Pharmacyclics LLC, An Abbvie Company1$14
Blue Earth Diagnostics1$13
Epizyme, Inc.1$12

How this compares

$5,734,264 in reported general payments places this provider in the 95th percentile of 450 hematology & oncology providers in Ohio.

See all hematology & oncology providers in Ohio →

Medicare billing

Part B allowed, 2024
$1,045,360
Medicare patients
270
Services billed
41,693

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Cincinnati

See the full list for Ohio →

Where these figures come from

Is this you, or does something look wrong? →